The gas-sensing capsule assesses the functional health of a patient’s entire gastrointestinal system and aims to provide: better diagnosis, more targeted and personalized treatment, earlier relief of symptoms and improved healthcare outcomes.
The capsule can electronically report important data by continuously detecting gases and wirelessly transmitting the data to provide insights into the location of the capsule, microbiome function and gastrointestinal health.
The ingestible capsule offers a potential diagnostic tool for many disorders of the gut from motility disorders, IBS and IBD to liver disease.
The Atmo Gas Capsule is currently an investigational device exclusively for use in clinical investigations, and is not available for sale.
Gut disorders are common and debilitating
Gut disorders are one of the most common ailments in the world affecting tens of millions of people.
These disorders include motility abnormalities, SIBO, IBS and IBD. Gases are important biomarkers of disease, dysfunction and dysbiosis.
AFFECTED
40% of global population suffer from a Functional Gastrointestinal Disorder (FGID).
UNDIAGNOSED
30% of patients remain undiagnosed and suffer from the recurrence of disorders.
SUFFERERS IN USA
IBS affects 25 to 45 million people in the USA and 2 to 5 million in Australia.
MARKET
GI disorders and disease treatment market (2013 USD).
How the Atmo Gas Capsule works
The vitamin-sized electronic “Lab-in-a-Pill” measures gaseous biomarkers at the source of production as it passes through the gastrointestinal system. This data is continuously transmitted to a pocket-sized receiver, and sent to the cloud for aggregation, analysis, and diagnosis.
The gas sensors are sealed within a special membrane that allows gas in but keeps out stomach acid and digestive juices.
The capsule aims to determine transit times derived from measures of temperature, relative humidity, hydrogen concentration, and carbon dioxide concentration, in conjunction with indicators of multi-gas, capsule tumble, and antenna reflectance.
News
-
Published editorial describes Atmo’s gas-sensing capsule as a “disruptive technology” enabling “step change” in approach to assessing colonic fermentation in IBS patients.
November 16, 2023. An editorial published in the journal Alimentary Pharmacology and Therapeutics describes Atmo Biosciences’ gas-sensing capsule as disruptive technology that has enabled unlocking ...
-
Atmo Biosciences and RMIT University granted Japanese Patent for ingestible gas-sensing capsule
November 13, 2023. Atmo Biosciences is pleased to announce that the Japan Patent Office has granted a patent related to key intellectual property for Atmo’s ingestible gas-sensing capsule....
-
Atmo Biosciences partners with ps.healthcare to expand Machine Learning (ML) and Artificial Intelligence (AI) capabilities
October 26, 2023. Atmo Biosciences today announced it is partnering with ps.healthcare to shape its data strategy, and create a roadmap of future applications using machine learning (ML) and artificia...
-
Study indicates Atmo Gas Capsule could be used to evaluate duodeno-gastric reflux in dysmotility patients.
October 19, 2023. The Atmo Gas Capsule could be used to help understand and monitor duodeno-gastric reflux and provide insight into its connection to delayed gastric emptying, according to an investig...
-
Atmo Biosciences reaches 60 per cent recruitment target in dysmotility pivotal clinical study
October 3, 2023. Atmo Biosciences has reached 60 per cent of its recruitment target for a pivotal clinical study to assess the use of the Atmo Gas Capsule to measure gastrointestinal transit time in p...
-
Breakthrough Victoria announces investment in Atmo Biosciences to help people with gut disorders
September 25, 2023. Breakthrough Victoria today announced it has invested in Atmo Biosciences to support the commercialization of the company’s world-first ingestible gas-sensing capsule that can he...
Media coverage
AUSBIZ
The tiny device revolutionising gut health diagnostics
24 September 2021
AUSTRALIAN FINANCIAL REVIEW
Gut health medtech Atmo Biosciences raises $9.6m
23 September 2021
BBC
Gas detecting pill could diagnose poor gut health
23 January 2018
“Gases produced in the gut are clinically valuable biomarkers for gastrointestinal health and dysfunction.”
Kalantar-Zadeh, K., Berean, K.J., Burgell, R.E. et al. Intestinal gases: influence on gut disorders and the role of dietary manipulations. Nat Rev Gastroenterol Hepatol 16, 733–747 (2019). https://doi.org/10.1038/s41575-019-0193-z
Medical Advisory Board
Prof. Eamonn Quigley (Chair)
David M. Underwood Chair of Medicine in Digestive Disorders and Chief of Gastroenterology and Hepatology.
Houston Methodist Hospital
Prof. Peter Gibson
Affiliated with
Monash University
Prof. William D. Chey
Chief of Gastroenterology and Hepatology.
University of Michigan
Prof. Satish Rao
Distinguished University Chair in Gastroenterology & Professor of Medicine. Director, Neurogastroenterology/Motility and Digestive Health Clinical Research Center.
Augusta University
Prof. Lin Chang
Professor of Medicine, Vice-Chief of the Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine.
David Geffen School of Medicine at UCLA
Prof. Anthony Lembo
Director of Research for Digestive Disease & Surgery Institute.
Cleveland Clinic
Assoc. Prof. Braden Kuo
Director of Center for Neurointestinal Health at Massachusetts General Hospital and Associate Professor at Harvard Medical School.
Board
Malcolm Hebblewhite
President & CEO, Co-Founder
Kate Hill
Chair of the Board & Non-Executive Director
Dr. Chris Roberts AO
Non-Executive Director
Chris Bertrand
Non-Executive Director
Operations
Dr. Kyle Berean
Head of Clinical Affairs & Co-Founder
Dr. James John
Head of Research and Development/Product Development & Co-Founder
Dr. Carl Runde
Chief Financial Officer & Company Secretary
Sue Dafnias
Head of Commercial
Dr. Adam Chrimes
Core Technology Lead & Co-Founder
Tajanka Mladenovska
Quality Assurance/Regulatory Affairs Manager
Matt Reeves
Manufacturing Manager
Advisory
Professor Kourosh Kalantar-zadeh
Lead Scientific Advisor
Partners
